4BB.L LSE
4basebio PLC
1W: +3.1%
1M: -11.2%
3M: -20.6%
YTD: -23.9%
1Y: -62.0%
3Y: -31.5%
5Y: +33.9%
£514.00 ($6.89)
+69.00 (+15.51%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Cap£74.3M ($1.0M)
52W Range420-1150
Volume2,472
Avg Volume1,289
Beta0.87
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAmy Jo Walker
Employees101
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-17
Website4basebio.com
25 Norman Way
Cambridge CB24 5QE
GB
Cambridge CB24 5QE
GB
44 1223 967 943
About 4basebio PLC
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
Latest News
4basebio (LON:4BB) Shares Down 7.7% – Should You Sell?
4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK
4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK
4basebio (LON:4BB) Stock Price Down 1.4% – What’s Next?
Recent Insider Trades
No insider trades found